Keros Therapeutics, Inc. (KROS) shareholders
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (13.27%), ADAR1 Capital Management GP, LLC (11.44%) | 5,389,264 | 13.27% | 13D (active) amendment | Aug 21, 2025 |
| Pontifax Management 4 GP (2015) Ltd. Joint filing with Pontifax (Israel) IV, L.P. (5.60%) | 4,787,331 | 11.80% | 13D (active) amendment | Apr 17, 2025 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (7.90%), Tang Capital Partners, LP (5.20%) | 2,418,984 | 7.90% | 13G (passive) | Oct 15, 2025 |
| ExodusPoint Capital Partners GP, LLC Joint filing with ExodusPoint Capital Management, LP (6.30%), Michael Gelband (6.30%) | 1,907,899 | 6.30% | 13G (passive) | Nov 10, 2025 |
| BlackRock Portfolio Management LLC | 1,813,870 | 9.10% | 13G (passive) amendment | Sep 30, 2026 |
| BlackRock, Inc. | 1,671,343 | 8.40% | 13G (passive) amendment | Jun 30, 2026 |
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (6.90%), Wilmot B. Harkey (6.90%) | 1,360,419 | 6.90% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KROS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2,820,838 | 14.23% | $30.18M | +1,460,419 | 0.50% |
| BlackRock, Inc. | 2,794,217 | 14.09% | $29.90M | +382,424 | 0.00% |
| Aqr Capital Management LLC | 967,859 | 4.88% | $10.36M | +561,296 | 0.00% |
| Vanguard Capital Management LLC | 833,596 | 4.20% | $8.92M | +2,175 | 0.00% |
| Orbimed Advisors LLC | 759,155 | 3.83% | $8.12M | – | 0.15% |
| Federated Hermes, Inc. | 700,427 | 3.53% | $7.49M | +11,198 | 0.01% |
| Vanguard Portfolio Management LLC | 652,635 | 3.29% | $6.98M | −29,408 | 0.00% |
| Mackenzie Financial Corp | 628,438 | 3.17% | $6.72M | +475,988 | 0.01% |
| Madison Avenue Partners, LP | 626,583 | 3.16% | $6.70M | – | 0.29% |
| Qube Research & Technologies Ltd | 608,837 | 3.07% | $6.51M | −116,089 | 0.01% |
| Jacobs Levy Equity Management, Inc | 605,445 | 3.05% | $6.48M | −100,626 | 0.02% |
| State Street Corp | 541,193 | 2.73% | $5.79M | −20,537 | 0.00% |
| Geode Capital Management, LLC | 510,841 | 2.58% | $5.47M | −170,619 | 0.00% |
| Dimensional Fund Advisors LP | 460,541 | 2.32% | $4.93M | +139,181 | 0.00% |
| Citadel Advisors LLC | 396,098 | 2.00% | $4.24M | −10,568 | 0.00% |
| Renaissance Technologies LLC | 359,086 | 1.81% | $3.84M | −94,396 | 0.01% |
| D. E. Shaw & Co., Inc. | 267,460 | 1.35% | $2.86M | −242,148 | 0.00% |
| Bridgeway Capital Management, LLC | 265,017 | 1.34% | $2.84M | +70,000 | 0.05% |
| Nuveen, LLC | 247,756 | 1.25% | $2.65M | −14,319 | 0.00% |
| ADAR1 Capital Management, LLC | 246,818 | 1.24% | $2.64M | +149,500 | 0.12% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 132 | 20M | 100.0% | 15 / 47 | 50 / 30 | 4M | 3M |
| Q1 2026 | 151 | 19M | 93.8% | 27 / 48 | 55 / 40 | 5M | 5M |
| Q4 2025 | 166 | 20M | 100.0% | 41 / 40 | 72 / 26 | 5M | 21M |
| Q3 2025 | 155 | 35M | 100.0% | 29 / 55 | 41 / 13 | 4M | 4M |
| Q2 2025 | 139 | 36M | 100.0% | 27 / 59 | 34 / 43 | 12M | 13M |
| Q1 2025 | 156 | 37M | 100.0% | 49 / 48 | 41 / 50 | 20M | 20M |
| Q4 2024 | 161 | 37M | 100.0% | 38 / 74 | 30 / 40 | 9M | 7M |
| Q3 2024 | 164 | 35M | 100.0% | 28 / 67 | 46 / 15 | 8M | 3M |
| Q2 2024 | 152 | 32M | 100.0% | 23 / 63 | 41 / 17 | 4M | 4M |
| Q1 2024 | 147 | 32M | 100.0% | 37 / 57 | 40 / 10 | 9M | 4M |
| Q4 2023 | 121 | 27M | 100.0% | 27 / 44 | 31 / 12 | 7M | 3M |
| Q3 2023 | 107 | 23M | 100.0% | 4 / 49 | 29 / 20 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
160 funds held KROS in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of KROS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 595,316 | 3.00% | $6.37M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 503,875 | 2.54% | $5.39M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 382,340 | 1.93% | $3.85M | 0.17% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 258,657 | 1.30% | $2.77M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 220,854 | 1.11% | $2.36M | 0.00% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 220,445 | 1.11% | $2.48M | 0.05% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 200,266 | 1.01% | $2.02M | 0.01% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 190,040 | 0.96% | $1.91M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 174,545 | 0.88% | $1.87M | 0.01% | Jun 30, 2026 |
| Vanguard Explorer Fund | 171,150 | 0.86% | $1.72M | 0.01% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 149,903 | 0.76% | $1.69M | 0.01% | May 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 149,300 | 0.75% | $1.60M | 0.01% | Jun 30, 2026 |
| Old Westbury Small & Mid Cap Strategies Fund | 143,853 | 0.73% | $1.45M | 0.02% | Jul 31, 2026 |
| U.S. Small Cap Value Portfolio | 142,035 | 0.72% | $1.43M | 0.01% | Jul 31, 2026 |
| iShares Biotechnology ETF | 128,504 | 0.65% | $1.37M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER, Director | 440,708 | 2.22% | Apr 6, 2026 |
| Lorena Raquel Lerner | Chief Scientific Officer | 27,559 | 0.14% | Aug 20, 2026 |
| Annita Tanini | Corp. Controller & VP, Finance | 45,144 | 0.23% | Aug 20, 2026 |
| Esther Cho | Chief Legal Officer | 35,770 | 0.18% | Aug 20, 2026 |
| Keith Regnante | CHIEF FINANCIAL OFFICER | 39,261 | 0.20% | Feb 26, 2026 |
| Yung H. Chyung | Chief Medical Officer | 44,000 | 0.22% | Feb 19, 2025 |
| Christopher Rovaldi | Chief Operating Officer | 60,000 | 0.30% | Feb 19, 2025 |
| Anne Prener | Director | 13,212 | 0.07% | Nov 16, 2026 |
| Charles W. Newton | Director | 12,114 | 0.06% | Aug 20, 2026 |
| Jean Jacques Bienaime | Director | 19,592 | 0.10% | Aug 19, 2026 |
| Nima Farzan | Director | 9,767 | 0.05% | Jun 8, 2026 |
| Julius Knowles | Director | 161,005 | 0.81% | Jun 8, 2026 |
| Mary Ann Gray | Director | 12,392 | 0.06% | Jun 5, 2026 |
| Alpna Seth | Director | 12,392 | 0.06% | Jun 5, 2026 |
| Carl L. Gordon | Director | 764,405 | 3.86% | Dec 18, 2025 |
| Genesis GP LLC OrbiMed | Director | 45,057 | 0.23% | Dec 18, 2025 |
| Capital GP VII LLC OrbiMed | Director | 148,922 | 0.75% | Dec 18, 2025 |
| Advisors Llc Orbimed | Director | – | – | Dec 18, 2025 |
| Ran Nussbaum | Director, 10% owner | 160,512 | 0.81% | Oct 17, 2025 |
| Tomer Kariv | Director, 10% owner | 160,512 | 0.81% | Oct 17, 2025 |
| (Cayman) IV L.P. Pontifax | 10% owner | – | – | Oct 17, 2025 |
| Pontifax (Israel) IV, L.P. | 10% owner | 1,122,768 | 5.66% | Oct 17, 2025 |
| (China) IV L.P. Pontifax | 10% owner | 10,500 | 0.05% | Oct 17, 2025 |
| Late Stage GP Ltd. Pontifax | 10% owner | 1,121,045 | 5.65% | Oct 17, 2025 |
| Late Stage Fund L.P. Pontifax | 10% owner | 2,288,151 | 11.54% | Oct 17, 2025 |
| Management 4 G.P. (2015) Ltd. Pontifax | 10% owner | – | – | Oct 17, 2025 |
| ADAR1 Capital Management GP, LLC | 10% owner | – | – | Oct 15, 2025 |
| Daniel Schneeberger | 10% owner | 0 | – | Oct 15, 2025 |
| ADAR1 Capital Management, LLC | 10% owner | – | – | Oct 15, 2025 |
| ADAR1 Partners, LP | 10% owner | 5,390,964 | 27.19% | Oct 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Anne Prener Director | Nov 12, 2026 | Sale(10b5-1 plan) | −574 | $9.79 | $5.62K | 13,212 |
| Charles W. Newton Director | Aug 18, 2026 | Sale(10b5-1 plan) | −551 | $10.30 | $5.68K | 12,114 |
| Annita Tanini Corp. Controller & VP, Finance | Aug 18, 2026 | Sale | −1,224 | $10.29 | $12.59K | 45,144 |
| Esther Cho Chief Legal Officer | Aug 18, 2026 | Sale | −4,485 | $10.29 | $46.15K | 35,770 |
| Lorena Raquel Lerner Chief Scientific Officer | Aug 18, 2026 | Sale | −3,568 | $10.29 | $36.71K | 27,559 |
| Jean Jacques Bienaime Director | Aug 17, 2026 | Buy | +1,000 | $10.27 | $10.27K | 19,592 |
| Jean Jacques Bienaime Director | Jul 15, 2026 | Buy | +1,000 | $10.61 | $10.61K | 18,592 |
| Anne Prener Director | Jul 1, 2026 | Award | +13,786 | – | – | 13,786 |
| Jean Jacques Bienaime Director | Jun 15, 2026 | Buy | +1,000 | $10.19 | $10.19K | 17,592 |
| Charles W. Newton Director | Jun 11, 2026 | Sale(10b5-1 plan) | −550 | $10.04 | $5.52K | 12,665 |
| Nima Farzan Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,625 | $10.73 | $28.17K | 9,767 |
| Julius Knowles Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,625 | $10.73 | $28.17K | 10,958 |
| Alpna Seth Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,625 | $10.72 | $28.14K | 9,767 |
| Julius Knowles Director | Jun 3, 2026 | Award | +7,142 | – | – | 13,583 |
| Nima Farzan Director | Jun 3, 2026 | Award | +7,142 | – | – | 12,392 |
| Mary Ann Gray Director | Jun 3, 2026 | Award | +7,142 | – | – | 12,392 |
| Jean Jacques Bienaime Director | Jun 3, 2026 | Award | +7,142 | – | – | 16,592 |
| Alpna Seth Director | Jun 3, 2026 | Award | +7,142 | – | – | 12,392 |
| Jean Jacques Bienaime Director | May 15, 2026 | Buy | +1,000 | $10.58 | $10.58K | 9,450 |
| Jean Jacques Bienaime Director | Apr 15, 2026 | Buy | +1,000 | $11.70 | $11.70K | 8,450 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | Apr 2, 2026 | Option exercise | +55,000 | $0.30 | $16.50K | 440,708 |
| Jean Jacques Bienaime Director | Mar 9, 2026 | Buy | +2,000 | $11.21 | $22.42K | 7,450 |
| Charles W. Newton Director | Mar 9, 2026 | Award | +13,215 | – | – | 13,215 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | Feb 19, 2026 | Sale | −7,015 | $16.17 | $113.43K | 385,708 |
| Esther Cho SVP, General Counsel | Feb 18, 2026 | Sale | −4,745 | $16.35 | $77.58K | 39,755 |
| Lorena Raquel Lerner Chief Science Officer | Feb 18, 2026 | Sale | −3,873 | $16.35 | $63.32K | 31,127 |
| Keith Regnante CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Sale | −4,739 | $16.35 | $77.48K | 39,261 |
| Carl L. Gordon Director | Nov 21, 2025 | Returned to company | −140,057 | $17.75 | $2.49M | 759,155 |
| Carl L. Gordon Director | Nov 21, 2025 | Returned to company | −74,465 | $17.75 | $1.32M | 45,057 |
| Genesis GP LLC OrbiMed Director | Nov 21, 2025 | Returned to company | −74,465 | $17.75 | $1.32M | 45,057 |
| Genesis GP LLC OrbiMed Director | Nov 21, 2025 | Returned to company | −140,057 | $17.75 | $2.49M | 759,155 |
| Julius Knowles Director | Nov 21, 2025 | Returned to company | −130,494 | $17.75 | $2.32M | 102,233 |
| Julius Knowles Director | Nov 21, 2025 | Returned to company | −191,527 | $17.75 | $3.40M | 150,047 |
| (China) IV L.P. Pontifax 10% owner | Oct 15, 2025 | Sale | −1,121,045 | $17.75 | $19.90M | 0 |
| (China) IV L.P. Pontifax 10% owner | Oct 15, 2025 | Sale | −1,226,412 | $17.75 | $21.77M | 0 |
| (China) IV L.P. Pontifax 10% owner | Oct 15, 2025 | Sale | −155,262 | $17.75 | $2.76M | 0 |
| (China) IV L.P. Pontifax 10% owner | Oct 15, 2025 | Sale | −2,284,612 | $17.75 | $40.55M | 0 |
| Daniel Schneeberger 10% owner | Oct 15, 2025 | Sale | −743,358 | $17.75 | $13.19M | 0 |
| Daniel Schneeberger 10% owner | Oct 15, 2025 | Sale | −4,391,237 | $17.75 | $77.94M | 0 |
| Daniel Schneeberger 10% owner | Oct 15, 2025 | Sale | −254,669 | $17.75 | $4.52M | 0 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | Sep 3, 2025 | Award | +90,500 | – | – | 392,723 |
| Daniel Schneeberger 10% owner | Jun 20, 2025 | Option exercise | −200 | $70.00 | $14.00K | 743,358 |
| Daniel Schneeberger 10% owner | Jun 20, 2025 | Option exercise | −100 | $60.00 | $6.00K | 4,392,637 |
| Daniel Schneeberger 10% owner | Jun 20, 2025 | Option exercise | −1,400 | $70.00 | $98.00K | 4,391,237 |
| Alpna Seth Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Carl L. Gordon Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Mary Ann Gray Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Jean Jacques Bienaime Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,450 |
| Ran Nussbaum Director, 10% owner | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Tomer Kariv Director, 10% owner | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Julius Knowles Director | Jun 4, 2025 | Award | +5,250 | – | – | 6,441 |
| Nima Farzan Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +74,333 | $10.33 | $767.86K | 4,392,737 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +18,560 | $9.40 | $174.46K | 3,493,404 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +16,365 | $9.40 | $153.83K | 743,558 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +325,000 | $9.86 | $3.20M | 3,818,404 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +500,000 | $10.33 | $5.17M | 4,318,404 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | Apr 4, 2025 | Option exercise | +49,367 | $0.30 | $14.81K | 302,223 |
| Keith Regnante CHIEF FINANCIAL OFFICER | Feb 18, 2025 | Award | +44,000 | – | – | 44,000 |
| Yung H. Chyung Chief Medical Officer | Feb 18, 2025 | Award | +44,000 | – | – | 44,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Keros Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 572 shares on Aug 26, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Charles W. Newton Director | Aug 18, 2026 | 551 | $5.72K | Aug 18, 2026 | RSU |
| Charles W. Newton Director | Jun 11, 2026 | 550 | $5.47K | Jun 11, 2026 | RSU |
| Alpna Seth Director | Jun 4, 2026 | 2,625 | $28.04K | Jun 4, 2026 | Restricted Stock Unit |
| Julius Knowles Director | Jun 4, 2026 | 2,625 | $28.04K | Jun 4, 2026 | Restricted Stock Unit |
| Nima Farzan Director | Jun 4, 2026 | 2,625 | $28.04K | Jun 4, 2026 | Restricted Stock Unit |
| OrbiMed Genesis Master Fund, LP Shareholder, Director | Mar 31, 2026 | 45,057 | $497.43K | Mar 31, 2026 | IPO |
| Christopher Rovaldi Affiliate | Sep 12, 2025 | 85,306 | $1.34M | Sep 12, 2025 | Exercise of Stock Options |
| OrbiMed Genesis Master Fund, LP Shareholder, Director | Aug 13, 2024 | 29,400 | $1.32M | Aug 13, 2024 | IPO |
| OrbiMed Private Investments VII, LP Shareholder, Director | Aug 13, 2024 | 220,600 | $9.89M | Aug 13, 2024 | IPO |
| Keith Regnante Officer | Jan 4, 2024 | 40,000 | $1.81M | Jan 4, 2024 | Exercise of stock options |
| The Biotech Growth Trust PLC Shareholder | Dec 11, 2023 | 246,000 | $8.77M | Dec 11, 2023 | Private placement |
| The Biotech Growth Trust PLC Shareholder | Jun 12, 2023 | 170,000 | $7.46M | Jun 12, 2023 | Private placement |
| Keith Regnante Officer | Jun 9, 2023 | 20,000 | $908.32K | Jun 9, 2023 | Exercise of Stock Option |
| Keith Regnante Officer | Jun 8, 2023 | 20,000 | $955.85K | Jun 8, 2023 | Exercise of stock options |
See a number that looks wrong?